-- 穆迪維持挪威政府Aaa長期發行人評級，展望穩定。 根據4月24日發布的消息，此評級確認基於挪威「異常強勁」的公共部門資產負債表、「極低」的債務可持續性風險、完善的製度體系、雄厚的財富水平以及政府全球養老基金資產提供的多元化配置。 同時，穩定的展望反映了挪威評等未面臨下行壓力。穆迪指出，挪威採取了有效的財政和貨幣政策來應對潛在衝擊。 在中東衝突的背景下，穆迪預計，能源價格上漲帶來的政府收入增加將被通膨上行壓力所抵消，因此對挪威信用狀況的影響「總體中性」。
Related Articles
Research
Mizuho Downgrades Adobe to Neutral From Outperform, Adjusts Price Target to $270 From $315
Adobe (ADBE) has an average rating of overweight and mean price target of $321.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ADBE
Treasury
US Treasury Yields Edge Up Pre-Bell as Iran's Hormuz Offer Delinks Deal With Nuclear Talks
US Markets
Organon Agrees to Be Acquired by Sun Pharmaceutical in $11.75 Billion Deal
Organon (OGN) shares spiked early Monday after the healthcare company agreed to be acquired by Indian pharmaceutical firm Sun Pharmaceutical Industries in an all-cash deal with an enterprise value of about $11.75 billion.Shareholders of Organon will receive $14 a share in cash under the terms of the transaction, the companies said in a joint statement on Sunday. Organon's stock jumped 15% in the most recent premarket activity."Following a comprehensive review of strategic alternatives, our board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders," Organon Chief Executive Carrie Cox said in the statement. "We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally."Organon, which focuses on women's health, was formed in 2021 following its separation from pharmaceutical giant Merck (MRK).The deal, which requires approval from regulators and clearance from Organon's shareholders, is expected to complete early next year."This transaction is a logical next step in strengthening Sun Pharma's global business," according to Sun Pharma Managing Director Kirti Ganorkar. "In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."Sun Pharma intends to fund the acquisition through a combination of available cash resources and committed financing from banks. The Indian company anticipates the transaction to allow it to enter the biosimilar market.For the year ended Dec. 31, Organon reported revenue of $6.22 billion and adjusted earnings before interest, taxes, depreciation and amortization of $1.91 billion. In February, the company said it expected revenue of $6.2 billion for the current year, while five analysts polled by FactSet estimate $6.15 billion.
$OGN